Blueprint Medicines Corporation
BPMC
Classificação em ações
#2354
Blueprint Medicines Corporation is a biopharmaceutical company dedicated to... Blueprint Medicines Corporation is a biopharmaceutical company dedicated to pioneering precision therapies. Its core mission involves developing innovative treatments for various cancers and specific blood disorders, specifically those identified by genomic markers. These efforts extend to patients both within the United States and across international markets. The company's robust pipeline includes several key therapies. AYVAKIT is being advanced for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors. They are also developing BLU-263, a potent, orally administered KIT inhibitor, designed for non-advanced forms of SM and other conditions involving mast cells. Fisogatinib, another orally potent inhibitor, is under development for hepatocellular carcinoma. GAVRETO is being developed to address RET fusion-positive non-small cell lung cancer (NSCLC), various altered solid tumors, and medullary thyroid carcinoma. Furthermore, BLU-701 and BLU-945 are in the pipeline for epidermal growth factor receptor (EGFR)-driven non-small-cell lung carcinoma, while BLU-451 targets NSCLC specifically in patients with EGFR exon 20 insertion mutations. The company's broader pipeline includes BLU-782 for fibrodysplasia ossificans progressiva, BLU-222 for cyclin E aberrant cancers, and BLU-852 for various advanced cancers. To expand its reach and capabilities, Blueprint Medicines has established collaboration and licensing agreements with several partners, including Clementia Pharmaceuticals, Proteovant Therapeutics, CStone Pharmaceuticals, Genentech, F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., and Zai Lab (Shanghai) Co., Ltd. Founded in 2008, the company was initially known as Hoyle Pharmaceuticals, Inc., before rebranding to Blueprint Medicines Corporation in June 2011. Its headquarters are located in Cambridge, Massachusetts.
Preço da ação
$129.46
Última sincronização: 2025-07-18
Valor de mercado
$8.36B
Variação (1 dia)
0.00%
Variação (1 ano)
0.00%
País
US
Negociar Blueprint Medicines Corporation (BPMC)
Categoria
Healthcare
Margem Operacional de Blueprint Medicines Corporation (BPMC)
Margem Operacional em October 2026 TTM: -41.67%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Blueprint Medicines Corporation, a margem operacional atual (TTM) é -41.67%. No final de 2023, a margem operacional era -194.99%.
Histórico da Margem Operacional da Blueprint Medicines Corporation de 2013 a 2026
Margem Operacional no final de cada ano
| Ano | Margem Operacional | Alterar |
|---|---|---|
| 2026 (TTM) | -41.67% | 0.00% |
| 2024 | -41.67% | -78.63% |
| 2023 | -194.99% | -27.56% |
| 2022 | -269.19% | -25.25% |
| 2021 | -360.10% | -1,045.89% |
| 2020 | 38.07% | -106.91% |
| 2019 | -551.16% | -0.67% |
| 2018 | -554.86% | -20.47% |
| 2017 | -697.64% | 163.22% |
| 2016 | -265.04% | -43.01% |
| 2015 | -465.10% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
Margem Operacional de empresas semelhantes ou concorrentes
| Empresa | Margem Operacional | Diferença na Margem Operacional | País |
|---|---|---|---|
| 38.59% | -100.93% |
US
|
|
| -149.01% | -96.42% |
US
|
|
| 25.57% | -100.61% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -100.69% |
NL
|
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.